Pure Global
NCT06262516

Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

Randomized-Controlled Trial Examining Oncologic and Perioperative Outcomes for Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma
Case Comprehensive Cancer Center·ClinicalTrials.gov·procedureNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
Nephroureterectomy
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Case Comprehensive Cancer Center
Location
Cleveland, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jul 01, 2024
End date
Jan 01, 2029
Enrollment
94 participants
Primary outcome

Recurrence-free survival

Summary

The goal of this study is to conduct the first randomized-controlled trial to determine the
 oncologic efficacy of lymph node dissection in participants with upper tract urothelial cell
 carcinoma. The main questions it aims to answer are:
 
 - To determine oncologic outcomes, specifically 2-year recurrence-free survival
 
 - To determine other oncologic outcomes including treatment-free, cancer-specific and
 overall survival
 
 - To determine time to recurrence and recurrence patterns
 
 - To determine use of adjuvant therapies
 
 - To determine perioperative complications
 
 Participants will undergo nephroureterectomy with or without lymph node dissection.
 Researchers will compare these two groups to determine the oncologic efficacy of performing
 lymph node dissection.

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06262516
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06262516 through Pure Global AI's free database. This phase not specified trial is sponsored by Case Comprehensive Cancer Center and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 94 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.